Výsledky vyhledávání - "Kari J Kurppa"

Akademický článek

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

Autor: Majid Momeny, Mari Tienhaara, Mukund Sharma, Deepankar Chakroborty, Roosa Varjus, Iina Takala, Joni Merisaari, Artur Padzik, Andreas Vogt, Ilkka Paatero, Klaus Elenius, Teemu D Laajala, Kari J Kurppa, Jukka Westermarck

Publikováno v: EMBO Molecular Medicine, Vol 16, Iss 7, Pp 1603-1629 (2024)

Abstract Despite clinical benefits of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can reactivate proliferation under TKI therapy. Here we present transcriptional profiling of HER2+ breast cancer cells transitioning from dormant drug tole

Externí odkaz: https://doaj.org/article/709f9a596c0c46e4951cbcebf8781895

Zobrazit plný text záznamu

Akademický článek

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

Autor: Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre PA Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus G Manz, Steffen Boettcher

Publikováno v: EMBO Molecular Medicine, Vol 16, Iss 3, Pp 445-474 (2024)

Abstract TP53-mutant acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric antigen receptor (CAR) T-cells might be a promising therapeutic option f

Externí odkaz: https://doaj.org/article/3995291a6c424aeaadea031a81b64f56

Zobrazit plný text záznamu

Akademický článek

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.

Autor: Kari J Kurppa, Matjaz Rokavec, Maria Sundvall, Pirkko-Liisa Kellokumpu-Lehtinen, Heikki Joensuu, Hiltrud Brauch, Klaus Elenius

Publikováno v: PLoS ONE, Vol 9, Iss 7, p e102388 (2014)

A number of genetic variants have been linked to increased risk of breast cancer. Little is, however, known about the prognostic significance of hereditary factors. Here, we investigated the frequency and prognostic significance of two ERBB4 promoter

Externí odkaz: https://doaj.org/article/a48ee157799c4ee89fbe08ab28602f03

Zobrazit plný text záznamu

Akademický článek

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)

Fusion genes have been proposed as a potential mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Here, the authors identify gene fusions that are associated with resistance to EGFR TKIs in non-small cell lung cancers,

Externí odkaz: https://doaj.org/article/0ceddd06c4bb4ffa905cd1128f416204

Zobrazit plný text záznamu

Table S3 from Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases

Autor: Klaus Elenius, Kari J. Kurppa, Mark S. Johnson, Mahlet Z. Tamirat, Deepankar Chakroborty, Marika K.A. Koivu

Table S3 shows primers used for site-directed mutagenesis.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84db7a622d9ed24a53724145a4a640f6
https://doi.org/10.1158/1535-7163.22521102.v1

Zobrazit plný text záznamu

An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations

Autor: Deepankar Chakroborty, Veera K. Ojala, Anna M. Knittle, Jasmin Drexler, Mahlet Z. Tamirat, Regina Ruzicka, Karin Bosch, Johanna Woertl, Susanne Schmittner, Laura L. Elo, Mark S. Johnson, Kari J. Kurppa, Flavio Solca, Klaus Elenius

Publikováno v: Cancer Research Communications. 2:10-27

Despite the relatively high frequency of somatic ERBB4 mutations in various cancer types, only a few activating ERBB4 mutations have been characterized, primarily due to lack of mutational hotspots in the ERBB4 gene. Here, we utilized our previously

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b50f9b74260d251a434e3536636cca24
https://doi.org/10.1158/2767-9764.crc-21-0021

Zobrazit plný text záznamu

RAF1 – MEK / ERK pathway‐dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation

Autor: Judith Pape, Shinsuke Fujii, Javier Catón, Kristiina Heikinheimo, Satsuki Shidara, Shinji Matsumoto, Tatsufumi Fujimoto, Tamotsu Kiyoshima, Eijiro Jimi, Kari J Kurppa, Megumi Kokura, Takuma Ishibashi, Peter Morgan, Akira Kikuchi

Publikováno v: The Journal of Pathology. 256:119-133

Ameloblastoma is an odontogenic neoplasm characterized by slow intraosseous growth with progressive jaw resorption. Recent reports have revealed that ameloblastoma harbours an oncogenic BRAFV600E mutation with mitogen-activated protein kinase (MAPK)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2faa41c0b18ad6c808c963f21667f6
https://doi.org/10.1002/path.5814

Zobrazit plný text záznamu

Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases

Autor: Klaus Elenius, Marika Koivu, Mahlet Z. Tamirat, Kari J. Kurppa, Mark S. Johnson, Deepankar Chakroborty

Publikováno v: Molecular Cancer Therapeutics. 20:564-576

Although targeted therapies can be effective for a subgroup of patients, identification of individuals who benefit from the treatments is challenging. At the same time, the predictive significance of the majority of the thousands of mutations observe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1accbd23a3165e967a19315a3569237
https://doi.org/10.1158/1535-7163.mct-20-0590

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání